2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - Hall B
This partial session is a mix of important abstracts of molecular observations in MPNs and Histiocytic Disorders. Suggested title (After discussion with other Lead reviewer Florian Heidel:  <blockquote type="cite" style="margin: 0px 10px !important; caret-color: #212121; color: #212121; font-family: Aptos; font-size: 16px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-line: none; text-decoration-thickness: auto; text-decoration-style: solid;"> <div> <div> <div style="direction: ltr; font-family: Aptos, Arial, Helvetica, sans-serif; font-size: 12pt;">Molecular Insights and New Approaches in MPNs</div> </div> </div> </blockquote>
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Biological Therapies, Non-Biological Therapies, Biological Processes, CHIP, Hematopoiesis, Metabolism, Diseases, Genetic Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

928 Sanreco phase 2 randomized, double-blind trial of divesiran in patients with polycythemia vera

Marina Kremyanskaya, MD, PhD, Alberto Martinez, PhD, MBA2, Curtis Rambaran, MD, PhD3, Andrew T Kuykendall, MD4, Naveen Pemmaraju, MD5, Florian H. Heidel IV, MD6, Alexandra Murton7, Valentín García Gutiérrez I, MD8, Indu Raman, MD9, Hanlon Sia, MBBS, FRACP, FRCPA10, Andrew Srisuwananukorn, MD11, Pencho Georgiev, MD12, Maria Laura Fox, MD13, Ahlam Kori, MD14, Heiko Becker, MD15, Andrew Charles Perkins, MBBS, PhD16, Akash Kalro I, MD17, Ping Chew, MD, MBBS, FRCP18, Azizan Sharif, MBBS19, Monia Marchetti, MD20, Henry Fok, MD PhD21, Monica Gomez-Palou, PhD22, Michael Szarek23, Ronald Hoffman, MD24
1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Silence Therapeutics plc, London, United Kingdom
3 Silence Therapeutics Inc, Hoboken, New Jersey, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 Hannover Medical School, Hannover, Germany
7 Royal Hobart Hospital, Hobart, Tasmania, Australia
8 Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
9 Epworth HealthCare, Melbourne, Australia
10 Pindara Private Hospital, Gold Coast, Australia
11 Ohio State University Medical School, Columbus, Ohio, United States
12 Medical University of Plovdiv, Plovdiv, Bulgaria
13 Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
14 Hospital Tengku Ampuan Afzan, Kuantan, Malaysia
15 Universitätsklinikum Freiburg, Freiburg, Germany
16 The Alfred Hospital, Melbourne, Victoria, Australia
17 Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
18 Hospital Umum Sarawak, Kurching, Malaysia
19 Hospital Sultanah Aminah, Johor Bahru, Malaysia
20 Ospedale Cardinal Massaia, Alexandria, Italy
21 Silence Therapeutics plc, London, United Kingdom
22 Silence Therapeutics plc, London, United Kingdom
23 University of Colorado School of Medicine, Aurora, Colorado, United States
24 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States

Background

Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by excessive production of red blood cells as reflected by elevated hematocrit (Hct) levels. PV patients (pts) are at an increased risk of developing thromboembolic events which are closely linked to elevated Hct levels (>45%) (Marchioli et al 2013). Hct levels are routinely controlled with phlebotomies (hl), in combination with cytoreductive therapies (CRT). Hepcidin, synthesized by hepatocytes, is the central regulator of iron homeostasis. In PV pts, it is expressed at relatively low levels (Ginzburg et al 2018). ) which are targeted precision medicines that engage and silence their mRNA targets.  Divesiran (SLN124) is a liver targeted GalNAc conjugated double stranded 19-mer siRNA that increases hepcidin hepatic synthesis and plasma levels by silencing TMPRSS6 (a negative regulator of hepcidin production), restricting iron availability for erythropoiesis and reducing hemoglobin (Hgb) and red blood cell production resulting in lower Hct.  In phase 1, the administration of divesiran in PV pts was well tolerated and resulted in sustained elevations of hepcidin levels, with reduction in Hct and Hgb resulting in substantial decrease in Phl (Kremyanskaya et al 2026, EHA Library S224). Here we present the design and preliminary data from the phase 2 part of the SANRECO trial (NCT05499013), a global study of divesiran in pts with PV.  Updated data will be presented at the conference.

Method

The phase 2 is a randomised placebo-controlled study in phlebotomy dependent PV patients. All pts had a diagnosis of PV as per 2016 WHO criteria and required ≥3 Phl in the 28 weeks or ≥5 Phl in the previous year with a Hct < 45% prior to dosing. All pts remained on standard of care treatment and received divesiran (6mg/kg) Q6W, Q12W or placebo in a 1:1:1 ratio for 36 weeks. The primary efficacy endpoint is the proportion of pts who achieve a response receiving divesiran compared to placebo between 18-36 weeks.  A responder is defined as a patient with Hct remaining <45% in the absence of Phl during weeks 18-36. and change in mean MPN total symptom score (MPN-SAF-TSS) Additional assessments include safety, pharmacokinetics and pharmacodynamic markers including but not limited to iron, and ferritin. after completion of the 36-week treatment period pts transition to a blinded extension where pts on divesiran continue on their treatment while placebo pts are randomised to either Q6W or Q12W dosing. Once a decision on a divesiran regimen for phase 3 is made, all pts may transition to an open label extension on the selected divesiran regimen. 

Results

The phase 2 study enrolled pts between December 2024 and October 2025, 65 pts were screened, 48 of whom were randomised to treatment with either placebo, divesiran at 6mg/kg Q6W or Q12W. 14 pts previously participated in the phase 1 and 34 pts were naïve to divesiran. The age was 55 years (range between 30 and 83), 30 (62.5%) were male, 35 (72.9%) were white, 10 (20.8%) were Asian, 3 (6.3%) were Hispanic, 24 (50%) were high risk (18/24 were age >60yrs, 4/24 prior thrombotic events (TE) and 2/24 were >60yrs and prior TE). JAK2V617F mutation was detected in 47 (97.9%). The mean (±SD) disease duration prior to the first dose was 61.6 ±46.4. Concurrent treatment included Phl alone in 18 pts (37.5%) or CRT in addition to Phl, 30 pts (62.5%) (24 hydroxyurea, 4 ruxolinitib and 8 interferon).  At baseline, mean (SEM) Phl/pts in the 28 weeks prior to dosing was 3.8 ± 0.33 with a mean rate of 0.14 ± 0.01 phl/pts/week.  Baseline mean (±SEM) Hct was 41.2% (±0.32) and Hgb 12.5g/dL (±1.6). Among all treated pts, most common treatment-emergent adverse events (TEAEs) were respiratory infections and injection site-reactions, no pts discontinued due to related TEAEs

Conclusions

The SANRECO phase 2 study of divesiran as a potential treatment for PV pts has enrolled 48 phlebotomy dependent pts. At the time of abstract submission, all patients had completed placebo-controlled portion of the study and data analysis is ongoing.   Full, unblinded results from the 36-weeks placebo-controlled portion of the study including reduction in Phl, improvement in Hct control, and the impact on quality of life and safety are expected in mid-August and will be included in the presentation at ASH.

Marina Kremyanskaya, MD, PhD: Kura - Honoraria; PharmaEssentia - Honoraria; Dompe - Research Funding; Kura - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Silence - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Protagonist - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony)